EVALUATION OF CYP2B6 INDUCTION AND PREDICTION OF CLINICAL DRUG-DRUG INTERACTIONS

被引：0
|
作者：
Fahmi, Odette A. [1 ]
机构：
[1] Pfizer, Pharmacokinet & Drug Metab, Groton, CT 06340 USA
来源：
DRUG METABOLISM AND PHARMACOKINETICS | 2017年 / 32卷 / 01期
关键词：
D O I：
10.1016/j.dmpk.2016.10.083
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
S62
引用
收藏
页码：S18 / S18
页数：1
相关论文
共 50 条
  • [21] Database analyses for drug-drug interactions involving CYP2D6 inhibition
    Ito, K
    Hallifax, D
    Obach, RS
    Houston, JB
    DRUG METABOLISM REVIEWS, 2003, 35 : 49 - 49
  • [22] In Silico Model for Predicting CYP2D6-Mediated Drug-Drug Interactions
    Lozano, Roberto
    Frutos, Alberto
    Martinez, Alejandro
    CURRENT REVIEWS IN CLINICAL AND EXPERIMENTAL PHARMACOLOGY, 2021, 16 (02) : 124 - 127
  • [23] Clinical and toxicological relevance of CYP2C9: Drug-drug interactions and pharmacogenetics
    Rettie, AE
    Jones, JP
    ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2005, 45 : 477 - 494
  • [24] Pharmacokinetics of the CYP3A4 and CYP2B6 Inducer Carbamazepine and Its Drug-Drug Interaction Potential: A Physiologically Based Pharmacokinetic Modeling Approach
    Fuhr, Laura Maria
    Marok, Fatima Zahra
    Hanke, Nina
    Selzer, Dominik
    Lehr, Thorsten
    PHARMACEUTICS, 2021, 13 (02) : 1 - 21
  • [25] THE EXTENT OF INHIBITION AND INDUCTION OF CYP2B6 BY EFAVRIENZ IS CYP2B6 GENOTYPE-DEPENDENT
    Duong, A.
    Gufford, B.
    Masters, A.
    Burgess, K.
    Lu, J.
    Metzger, I.
    Desta, Z.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S36 - S36
  • [26] Prediction of Drug-Drug Interactions Related to Inhibition or Induction of Drug-Metabolizing Enzymes
    Dmitriev, Alexander, V
    Lagunin, Alexey A.
    Karasev, Dmitry A.
    Rudik, Anastasia, V
    Pogodin, Pavel, V
    Filimonov, Dmitry A.
    Poroikov, Vladimir V.
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2019, 19 (05) : 319 - 336
  • [27] TRACING CYP INDUCTION: A NOVEL APPROACH TO MEET FDA RECOMMENDATIONS ON DRUG-DRUG INTERACTIONS
    Boriss, Hinnerk
    Rautio, Jari
    DRUG METABOLISM REVIEWS, 2014, 45 : 127 - 127
  • [28] Efavirenz and CYP2B6 polymorphism:: Implications for drug toxicity and resistance
    Nolan, D
    Phillips, E
    Mallal, S
    CLINICAL INFECTIOUS DISEASES, 2006, 42 (03) : 408 - 410
  • [29] Insights into CYP2B6-mediated drug–drug interactions
    William D.Hedrich
    Hazem E.Hassan
    Hongbing Wang
    ActaPharmaceuticaSinicaB, 2016, 6 (05) : 413 - 425
  • [30] Application of in vitro CYP and transporter assays to predict clinical drug-drug interactions
    Volpe, Donna A.
    Balimane, Praveen V.
    BIOANALYSIS, 2018, 10 (09) : 619 - 623
12345